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Abstract
At 30 years into the HIV infection epidemic, the optimal antiretroviral (ARV) regimen for infected patients with cancer remains unknown.
We therefore sought to retrospectively study different ARV regimens used in this population. Data from HIV-infected patients seen at The
University of Texas MD Anderson Cancer Center in Houston, Texas, USA, from 2001 to 2012 were reviewed. Patients received nucleoside
reverse transcriptase inhibitors (NRTIs) plus protease inhibitors (PIs), non-NRTIs (NNRTIs), integrase strand-transfer inhibitors (INSTIs),
or combinations of these. A total of 154 patients were studied. Most patients were male (80%), white (51%) and had haematological
malignancies (HMs) (58%). NRTIs were combined with PIs (37%), NNRTIs (32%), INSTIs (19%) or combinations of these (11%). INSTIs
were the most commonly used in patients with HM and in those receiving high-dose steroids or topoisomerase inhibitors (p <0.05).
Side-effects occurred in 35%, 14%, 3% and 6% of patients receiving PIs, NNRTIs, INSTIs and combinations, respectively (p 0.001). Grade 3–4
adverse events were uncommon. Multivariate logistic regression analysis demonstrated that INSTIs and NNRTIs were nine times (95%
conﬁdence interval (CI), 1.4–50.8) and 11 times (95% CI, 1.9–64.7) more likely to be effective at 6 months, respectively, than PIs. This is the
largest reported analysis studying different ARV regimens in HIV-infected cancer patients. Combinations that included PIs were the least
favourable. NNRTIs and INSTIs had comparable efﬁcacy, but INSTIs appeared to be the better tolerated ARVs in patients with HM or those
receiving various chemotherapeutic agents.
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Introduction
Several studies have suggested that the rates of acquired
immunodeﬁciency syndrome (AIDS)-related cancers (e.g. Ka-
posi sarcoma (KS), non-Hodgkin lymphoma (NHL) and cervical
cancer) have decreased greatly but that the incidence of
non-AIDS-associated malignancies (e.g. cancers of the head
and neck, lung, kidney, liver, gastrointestinal tract, anus, and
skin (squamous cell carcinoma, basal cell carcinoma, and
melanoma), Hodgkin lymphoma and leukaemia) in patients
with chronic human immunodeﬁciency virus (HIV) infection
have increased [1–4]. Regardless of the type of cancer in
HIV-infected patients, malignancies now account for about
33% of all HIV-related deaths [5,6].
The need for treatment of cancer and HIV infection with
concurrent antineoplastic agents and antiretrovirals (ARVs) is
increasingly common [7]. Use of such simultaneous therapy
reduces morbidity associated with opportunistic infections and
improves overall survival rates in patients with HIV-related
malignancies [8]. For example, concurrent ARV-based treat-
ment and chemotherapy improves long-term outcomes in
patients with AIDS-associated lymphoma [9,10].
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Initiation and optimization of ARV-based therapy are
recommended for HIV-infected cancer patients [11], but the
optimal ARV regimens for these patients are unknown.
Treating cancer in patients with HIV receiving ARVs is
complicated because of a dearth of clinical understanding of
potential drug interactions among cytotoxic and targeted
antineoplastic agents and ARVs [3,7]. Combining antineoplastic
agents and ARVs is accompanied by the potential for drug
accumulation, overlapping toxic effects, and harmful effects of
chemotherapy on immune status, decreasing the efﬁcacy of
one or both classes of drugs [4,7,8]. As a consequence, little
information exists regarding the concomitant treatment of HIV
infection and cancer, as HIV-infected patients are typically
excluded from clinical trials of chemotherapeutic agents [7].
Clinicians caring for HIV-infected cancer patients are still in
search of ARVs that are safe and effective in this population as
guidelines for which ARVs to use in the setting of HIV and
cancer are lacking. Therefore, in the present study, we
retrospectively assessed the efﬁcacy and safety of various
ARVs in either treatment-na€ıve or previously treated HIV-
infected patients who had cancer or underwent haematopoi-
etic stem cell transplantation (HSCT) at The University of
Texas MD Anderson Cancer Center, Houston, Texas, USA.
Materials and Methods
All HIV-positive patients with any type of cancer (AIDS- and/or
non-AIDS-deﬁning malignancies) seen from January 2001 to
December 2012 were identiﬁed by searching institutional
databases. Individual patient charts were reviewed for demo-
graphics, past medical history, date of HIV and cancer
diagnosis, cancer type, co-infections, history of opportunistic
infections, use of chemotherapy or immunosuppressive regi-
mens, cancer treatment with associated complications, CD4+
lymphocyte count, HIV viral load, duration of ARV regimen,
virological response to ARV regimen and its potential side-
effects, and outcome.
Only patients who made regular clinic visits (at least two in
a 6-month period), and whose treatment was initiated or
monitored by MD Anderson infectious diseases specialists,
were included. ARV-na€ıve or ARV-treatment-experienced
adults with HIV/AIDS were included. The patients’ ARV
regimens were identiﬁed by searching the Division of Phar-
macy database. Variations in CD4 T-cell count were not used
as indicators of treatment response, as they can be affected by
malignancies or their treatment (e.g. chemotherapy, predni-
sone). Likewise, changes in haematological parameters while
on ARVs were not analysed because of the overlapping effects
of many cancers or antineoplastic agents on bone marrow
function. The sponsor of the study had no role in study design,
data collection, analysis or interpretation, or manuscript
writing. Our protocol was approved by the MD Anderson
Institutional Review Board.
Clinically relevant drug interactions (either predictable or
not) were deﬁned as those resulting in adjustment of doses or
discontinuation of co-administered agents. Speciﬁc clinically
relevant interactions of ARVs with drugs commonly used to
treat cancer were identiﬁed. These drugs included antifungal
triazoles (e.g. voriconazole and posaconazole), immunosuppres-
sants (tacrolimus and cyclosporine) and antineoplastic agents
(e.g. alkylating agents, anthracyclines and taxanes). Clinical stage
of HIV infection was deﬁned as previously described [12]. ARV
efﬁcacy was deﬁned as the absence of virological failure (HIV
RNA ≥200 copies/mL ≥ 6 months on an ARV regimen initiated
or monitored at MD Anderson) or virological rebound (two
consecutive plasma HIV RNA >200 copies/mL after virological
suppression) [1]. The 6-month follow-up period began at the
time of initial evaluation at our centre.
Outcomes of the treatments were reviewed in terms of
safety, drug interactions and ARV efﬁcacy. The primary
endpoints were safety and tolerability, including adverse events,
side effects and clinically relevant drug interactions. The
Division of AIDS (DAIDS) table for grading the severity of
adult and paediatric adverse events was used for grading the
intensity of clinical events and laboratory abnormalities. The
secondary endpoint was efﬁcacy. The data analyses consisted of
four-group comparisons including patients treated with nucle-
oside reverse transcriptase inhibitors (NRTI) backbone plus (i)
PIs, (ii) NNRTIs, (iii) INSTIs or (iv) combinations of these. The
chi-square or Fisher exact test was used to compare categorical
variables. If a signiﬁcant result (p 0.05) was detected, pairwise
comparisons between individual groups were performed to
identify the signiﬁcant differences. The Kruskal–Wallis test was
used to compare continuous variables. If a signiﬁcant result was
detected, the Wilcoxon rank sum test was used for the
pairwise comparisons. The a levels of the post hoc pairwise
comparisons were adjusted using the sequential Bonferroni
method to control for type I errors. In addition, logistic
regression analysis was used to identify predictive factors for
efﬁcacy and mortality. All tests except those in the pairwise
comparisons were two-sided at a signiﬁcance value of 0.05. The
statistical analyses were performed using the SAS software
program (version 9.3; SAS Institute Inc., Cary, NC, USA).
Results
A total of 154 cancer patients seen during the study period with
HIV infection and available ARV data were included in the
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analysis. Most of the patients were male (n = 123, 80%) and
white (n = 79, 51%). The most common underlying malignancy
was haematological (n = 90, 58%), primarily NHL (n = 64,
71%). Among the 64 patients with solid tumours, most had
gastrointestinal cancer (n = 20, 31%). Nineteen patients (12%)
underwent HSCT, and most of the transplants were autologous
(n = 15, 79%). INSTIs were the most common ARVs used in
patients with haematological malignancies (p 0.001; Table 1).
The most common NRTIs were tenofovir (104 patients,
68%) or abacavir (22 patients, 14%) in combination with
emtricitabine or lamivudine. NRTI backbone was combined
with PIs (57 patients, 37%), NNRTIs (50 patients, 32%), INSTIs
(30 patients, 19%), or a combination of these (17 patients,
11%) (Table 1). Raltegravir was the only INSTI available during
the study period.
The different cancer treatment modalities administered to
HIV-infected patients receiving ARVs are depicted in Table 2.
Chemotherapy agents used included taxanes (paclitaxel and
docetaxel), vinca alkaloids (vincristine, vinblastine and vinorel-
bine), topoisomerase inhibitors (etoposide, irinotecan and
topotecan), alkylating agents (cyclophosphamide, ifosfamide,
dacarbazine, procarbazine, melphalan, cisplatin, carboplatin,
carmustine, oxaliplatin and mechlorethamine), antimetabolites
(methotrexate, 5-Fluorouracil, cytarabine, ﬂudarabine, gemcit-
abine, decatinib, hydroxyurea, azacitidine and capecitabine),
antitumour antibiotics (doxorubicin, bleomycin and mitomy-
cin), targeted therapy (rituximab, cetuximab, geﬁtinib, bort-
ezomib, ofatumumab, trastuzumab, panituximab, erlotinib and
sorafenib), endocrine/hormone therapy (anastrozole, leupro-
lide and bicalutamide), and miscellaneous agents (L-asparagin-
ase). Statistically or numerically, INSTIs were the most
common ARVs used in patients concomitantly receiving
high-dose steroids, topoisomerase inhibitors, alkylating agents
or antimetabolites (Table 2).
The 6-month efﬁcacy rates of INSTIs and NNRTIs were
comparable (96% and 97%, respectively; p >0.99). Both rates
were superior to that of PIs (65%; p 0.005 and p 0.001,
respectively) (Table 3). Baseline HIV RNA levels (odds ratio
(OR), 1.33; 95% CI, 0.5–3.9; p 0.61) and nadir CD4 cell count
(OR, 1.0; 95% CI, 0.99–1.0; p 0.2) were not associated with
6-month efﬁcacy after adjusting for ARV groups. Multivariate
logistic regression analysis of predictive factors for ARV
efﬁcacy at 6 months demonstrated that the type of ARVs
concomitantly used (p 0.004) was signiﬁcantly associated with
ARV efﬁcacy at 6 months. Compared with PIs, INSTIs were
nine times (95% CI, 1.4–50.8) more likely to be effective at
6 months, whereas NNRTIs were 11 times (95% CI, 1.9–64.7)
more likely to be effective at 6 months.
Infectious disease specialists, oncologists and pharmacists
reviewed the ARV regimens to minimize drug interactions. In
this controlled setting, clinically relevant drug interactions
were uncommon, occurring only in those who received PIs
(4%). We observed only two clinically signiﬁcant drug inter-
actions: one in a patient receiving a PI regimen and cyclospor-
ine and the other in a patient receiving nevirapine and
mirtazapine. In 11 (7%) patients, the physicians changed the
initial ARV regimen in anticipation of potential interactions
with chemotherapeutic or antifungal agents (e.g. voriconazole).
Speciﬁcally, in nine patients, physicians switched from NNRTIs
(efavirenz and etravirine) or PIs (ritonavir-boosted darunavir
or lopinavir) to INSTIs. In two patients, they switched from an
NNRTI (efavirenz) to a PI. ARV-related side-effects occurred
in 35%, 14%, 3% and 6% of patients receiving PIs, NNRTIs,
INSTIs or combinations, respectively (p 0.001). Grade 3–4
adverse events were uncommon. There was no correlation
between ARV duration and occurrence of side-effects after
accounting for ARV groups (OR, 1.0; 95% CI, 0.99–1.02;
p 0.17), probably due to the small number of adverse events in
some groups (Table 4). None of the patients had immune
reconstitution syndrome.
Numerically, interruption of ARV-based treatment was less
common in patients receiving INSTIs than in those receiving
PIs or NNRTIs (7%, 28% and 26%, respectively). The ARV/
chemotherapy combinations that were demonstrated to be
safe are shown in Fig. 1.
The overall mortality rates were 46%, 36%, 13% and 41% in
the patients receiving PIs, NNRTIs, INSTIs and combinations,
respectively (p 0.03). Progression of cancer was the most
common cause of death in all treatment groups. Logistic
regression analysis of predictive factors for death showed that
cancer status (p <0.0001) was the only factor independently
associated with death.
Discussion
At 30 years into the HIV infection epidemic, the optimal ARV
regimen for infected patients with cancer remains unknown. In
the present study, the largest analysis of different ARVs
administered to HIV-infected patients with cancer to date, we
made several important observations. First, PI regimens are
less efﬁcacious than NNRTI and INSTI regimens in this patient
population. Second, the efﬁcacy of NNRTIs is comparable with
that of INSTIs. Third, NNRTI and INSTI regimens have a
better safety proﬁle than PI regimens. Fourth, INSTIs are well
tolerated in patients with haematological malignancies or those
receiving concomitant steroids or various chemotherapeutic
agents and were chosen when potential interactions with
chemotherapeutic or antifungal agents were anticipated.
These ﬁndings should aid infectious diseases specialists and
ª2014 The Authors
Clinical Microbiology and Infection ª2014 European Society of Clinical Microbiology and Infectious Diseases, CMI, 20, O672–O679
O674 Clinical Microbiology and Infection, Volume 20 Number 10, October 2014 CMI
TABLE 1. General characteristics of the HIV-infected patients with cancer according to ARV regimen (n = 154)
Characteristic
Number of patients (%)
p Value
NRTIs + INSTI
(n = 30)
NRTIs + PI
(n = 57)
NRTIs + NNRTI
(n = 50)
Combination
(n = 17)a
Median age, years (range) 51 (21–68) 50 (29–74) 48 (30–82) 53 (38–67) 0.49
Male sex 24 (80) 42 (74) 41 (82) 16 (94) 0.3
Race
White 19 (63) 30 (53) 22 (44) 8 (47) 0.55
Black 8 (27) 21 (37) 15 (30) 6 (35)
Hispanic 2 (7) 5 (9) 10 (20) 3 (18)
Others 1 (3) 1 (2) 3 (6) 0
Type of cancer
Haematological 25 (83) 24 (42) 34 (68) 7 (41) <0.001b
NHL 17 (68) 19 (79) 24 (71) 4 (57)
HL 3 (12) 3 (13) 5 (15) 1 (14)
Leukaemia 5 (20) 1 (4) 3 (9) 1 (14)
Myeloma 0 1 (4) 2 (6) 1 (14)
Solid tumour 5 (17) 33 (58) 16 (32) 10 (59)
GI 2 (40) 11 (33) 4 (25) 3 (30)
Prostate 0 5 (15) 3 (19) 1 (10)
Lung 0 2 (6) 3 (19) 2 (20)
Breast 0 1 (3) 4 (25) 0
Melanoma 0 1 (3) 0 2 (20)
Othersc 3 (60) 13 (39) 2 (13) 2 (20)
HSCT 5 (17) 2 (4) 10 (20) 2 (12) 0.04d
Autologous 2 (40) 2 (100) 9 (90) 2 (100)
Allogeneic 3 (60) – 1 (10) –
Cancer status
Complete remission 16 (53) 26 (46) 28 (56) 9 (53) 0.95
Progressive disease 9 (30) 20 (35) 17 (34) 6 (35)
Partial remission 1 (3) 1 (2) 1 (2) 0
Stable disease 4 (13) 10 (18) 4 (8) 2 (12)
HIV infection status
Positive before cancer diagnosis 17 (57) 46 (81) 32 (64) 17 (100) 0.009
Diagnosed along with cancer 10 (33) 9 (16) 16 (32) –
ARV status at cancer diagnosis
Na€ıve 15 (50) 18 (33) 23 (46) 0 0.003
Experienced 15 (50) 37 (67) 27 (54) 17 (100)
Length of ARV therapy, months, median (range) 19 (8–272) 48 (6.5–206) 32 (7–132) 65 (2–208) 0.008e
Clinical stage of HIV infection at baseline
Stage 1 4 (13) 11 (19) 9 (18) 3 (18) 0.11
Stage 2 7 (23) 10 (18) 6 (12) 5 (29)
Stage 3 (AIDS) 19 (64) 27 (47) 23 (46) 6 (35)
Stage unknown 0 (0) 9 (16) 12 (24) 3 (18)
Baseline HIV-RNA, copies/mL, median (range) 1100 (0–872 000) 386 (0–4 530 000) 52 (0–4 230 000) 47 (0–1 260 000) 0.15
<100 000 24 (80) 39 (71) 34 (69) 10 (59) 0.48
Baseline CD4 cell count, cells/mm3, median (range) 120 (4–888) 167 (3–1,143) 181 (7–1444) 264 (21–865) 0.59
Nadir CD4 cell count, cells/mm3, median (range) 86 (3–390) 63 (2–724) 75 (1–646) 100 (3–298) 0.92
HIV resistant mutations 7 (58) 10 (77) 4 (44) 1 (50)
Treatment na€ıve 7 (100) 5 (50) 4 (100) 0 (0)
RT mutations only 2 (29)f 0 (0) 0 (0) –
PI mutations only 1 (14)g 4 (80)h 4 (100)i –
Both mutations 4 (57)j 1 (20)k 0 (0) –
Treatment experienced 0 (0) 5 (50) 0 (0) 1 (100)
RT mutations only – 2 (40)l – 0 (0)
PI mutations only – 0 (0) – 0 (0)
Both mutations – 3 (60)m – 1 (100)n
HL, Hodgkin’s lymphoma; GI, gastrointestinal.
aPIs only (four patients), HIV fusion inhibitors (one patient), NRTI backbone plus NNRTIs plus PIs (three patients), NRTI backbone plus PIs plus INSTIs (one patient), NNRTIs plus
PIs plus INSTIs (three patients), NNRTIs plus INSTIs (one patient), NRTI backbone plus NNRTIs plus INSTIs (one patient), PIs plus INSTIs (two patients), or NNRTIs plus PIs (one
patient).
bNRTI backbone + INSTI vs. NRTI backbone + PI, p <0.001; NRTI backbone + INSTI vs. combination, p 0.003; NRTI backbone + PI vs. NRTI backbone + NNRTI, p 0.007.
cOther solid tumours: cancer of nasopharynx (n = 1), urethra (n = 1) and squamous cell carcinoma (SCC) of oral cavity (n = 1) in NRTIs + INSTI group; SCC of mandible (n = 2),
SCC of cervix (n = 2), SCC of vulva (n = 2), SCC of larynx (n = 2), SCC of skin (n = 2), SCC of tongue (n = 1), SCC of maxillary sinus (n = 1) and cancer of thymus (n = 1) in
NRTIs + PI group; basal cell carcinoma of nasal vestibule (n = 1) and SCC of paranasal sinuses (n = 1) in NRTIs + NNRTIs group; metastatic carcinoma of unknown primary
(n = 1) and SCC of tongue (n = 1) in combination group.
dNRTI backbone + INSTI vs. NRTI backbone + PI, p 0.047; NRTI backbone + PI vs. NRTI backbone + NNRTI, p 0.01.
eNRTI backbone + INSTI vs. NRTI backbone + PI, p 0.01; NRTI backbone + INSTI vs. combination, p 0.02; NRTI backbone + PI vs. combination, p 0.06; NRTI
backbone + NNRTI vs. combination, p 0.008.
fNNRTI mutation (V108I (n = 2)).
gPI mutation (L10V).
hNRTI mutations (D67N, K219Q, M184I, T69N, T215V), NNRTI mutations (K103S, V90I, V118I (n = 2), V179D/E), PI mutations (A71T, I62V (n = 2), K20R, L63P (n = 2), M36I
(n = 2), V77I (n = 2), I93L).
iPI mutations (A71T, I13V (n = 3), I62V (n = 2), I93L, L10I, L63P (n = 2), L63P/T (n = 2), V77I (n = 2)).
jNNRTI mutations (V90I), PI mutations (A71T, I13V, L63P, M36I).
kNNRTI mutations (Y181C, 103N, 135WT/M, 188WT/C).
lNRTI mutations (70R, 67N, 184V, L210W, M41L, M184V (n = 2), T215Y), NNRTI mutations (K103N, L100I), PI mutations (46I, 71T, I47A, I54V, I63V, K20R, L63P, L89M, L10I
(n = 2), V32I, V77I, V82A).
mPI mutations (A71V, L10I, M36I (n = 2)).
nNRTI mutations (L210W, M41L, M184I, T69D, T215Y), NNRTI mutations (K103N, Y181C), PI mutations (A71T, I13V, I15V, I54V, K20I, L10I, L63P, L90M, M46I, Q58E,
V71I).
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oncologists in clinical decision-making regarding selection of
the most appropriate ARVs for HIV-infected cancer patients
receiving chemotherapy.
At present, guidelines are lacking for ARV-based treatment
in cancer patients receiving chemotherapy, partly because
patients with HIV infection are excluded from studies of
cancer drugs [13]. Therefore, the clinician’s dilemma is how to
administer therapy to patients who need treatment with
anticancer drugs in light of the propensity for interactions of
these drugs with ARVs [7].
In several studies, researchers have investigated how ARVs
are metabolized and how they induce and inhibit the activity of
various enzymes involved in drug metabolism [3,14]. The
majority of ARVs (NNRTIs, PIs and chemokine receptor
antagonists) are metabolized via the cytochrome P450
(CYP450) pathway [10]. Likewise, many chemotherapeutic
agents are metabolized by CYP450. Therefore, the potential
for interactions of these agents with ARVs is great. Bidirec-
tional interactions of ARVs with other classes of anticancer
agents, including alkylating agents, corticosteroids, epipodo-
phyllotoxins, taxanes, tyrosine kinase inhibitors and vinca
alkaloids, also may occur [7]. Anthracyclines, antimetabolite
agents, antitumour antibiotics and platinums undergo non--
CYP450 routes of elimination and are unlikely to be altered by
ARV [7]. A drug interaction is predicted between ritonavir,
which induces the phase I detoxifying enzyme CYP3A2, and
sorafenib, a substrate of this enzyme [15].
In addition, some ARVs are known to induce over-expres-
sion of CYP450 enzymes. For instance, nevirapine, efavirenz,
ritonavir and tipranavir induce CYP450 3A4 expression [3].
This induction of enzyme expression can increase the elimi-
nation from the body of other drugs that undergo similar
metabolism. Metabolism-related drug interactions involving
NRTIs are minimal because these agents are not eliminated by
the CYP450 system, nor do they induce or inhibit CYP450
enzymes [8]. PIs and NNRTIs are extensively metabolized by
TABLE 2. Chemotherapy, immunosuppressive agents and radiotherapy administered to HIV-infected patients with cancer
receiving ARVs
Treatment
Number of patients (%)
NRTIs + INSTI
(n = 30)
NRTIs + PI
(n = 57)
NRTIs + NNRTI
(n = 50)
Combination
(n = 17) p Value
Cytotoxic drugs 26 (87) 37 (65) 39/49 (80) 12 (71) 0.12
Taxanes 1 (3) 4 (7) 2 (4) 3 (18) 0.24
Vinca alkaloids 13 (43) 14 (25) 16 (32) 3 (18) 0.2
Topoisomerase inhibitors 13 (43) 8 (14) 10 (20) 3 (18) 0.016a
Alkylating agents 21 (70) 26 (46) 23 (46) 6 (35) 0.07b
Antimetabolites 16 (53) 13/50 (26) 16 (32) 7 (41) 0.08c
Antitumour antibiotics 12 (40) 14 (25) 17 (34) 3 (18) 0.28
Targeted therapy 10 (33) 18 (32) 18 (36) 5 (29) 0.95
Endocrine/hormone therapy 0 1/50 (2) 4 (8) 0 0.35
Miscellaneous agents 1 (3) 0 0 0 0.31
Investigational agents 0 1 (2) 1 (2) 1 (6) 0.61
Immunosuppressive drugs
Corticosteroids 26 (87) 39/54 (72) 40/46 (87) 13/15 (87) 0.19
>600 mg (prednisone equivalent), mg 24/26 (92) 20/34 (59) 28/36 (78) 9/13 (69) 0.023d
Other immunosuppressants 2 (7)e 3 (5)f 0 0 0.27
Radiotherapy 11 (37) 27/55 (49) 20 (40) 9 (53) 0.55
aNRTI backbone + INSTI vs. NRTI backbone + PI, p 0.002; NRTI backbone + INSTI vs. NRTI backbone + NNRTI, p 0.026.
bNRTI backbone + INSTI vs. NRTI backbone + PI, p 0.03; NRTI backbone + INSTI vs. NRTI backbone + NNRTI, p 0.04; NRTI backbone + INSTI vs. combination, p 0.02.
cNRTI backbone + INSTI vs. NRTI backbone + PI, p 0.014.
dNRTI backbone + INSTI vs. NRTI backbone + PI, p 0.004.
eTacrolimus in both patients.
fSirolimus, mycophenolate acid and cyclosporine in one patient each.
TABLE 3. Efﬁcacy of ARV-based treatment of HIV infection in cancer patients
Efﬁcacy NRTI + INSTI (%) NRTI + PI (%) NRTI + NNRTI (%) Combination (%) p Value
At 6 months 23/24 (96) 30/46 (65) 30/31 (97) 7/9 (78) <0.001a
Na€ıve 12/12 (100) 9/15 (60) 18/18 (100) – <0.001b
Experienced 11/12 (92) 20/30 (67) 12/13 (92) 7/9 (78) 0.2
At 1 year 7/7 (100) 15/25 (60) 22/24 (92) 8/9 (89) 0.017c
Na€ıve 5/5 (100) 5/8 (63) 9/9 (100) – 0.04
Experienced 2/2 (100) 9/16 (56) 13/15 (87) 8/9 (89) 0.18
Non-compliant patients were excluded.
aNRTI backbone + INSTI vs. NRTI backbone + PI, p 0.005; NRTI backbone + PI vs. NRTI backbone + NNRTI, p 0.001.
bNRTI backbone + INSTI vs. NRTI backbone + PI, p 0.02; NRTI backbone + PI vs. NRTI backbone + NNRTI, p 0.005.
cNRTI backbone + PI vs. NRTI backbone + NNRTI, p 0.01.
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and induce or inhibit the CYP450 system, creating a high
potential for drug interaction [7]. Maraviroc is a substrate of
both the CYP450 3A enzyme and ABCB1 transporter and is
susceptible to interactions with many drugs [7]. Furthermore,
to varying degrees, all PIs inhibit CYP450 3A4 activity [3]. In
comparison, raltegravir undergoes glucuronidation via
UDP-glucuronosyltransferase 1A1 (UGT1A1) and has less
potential for drug interactions than PIs and NNRTIs [16].
To better understand potential drug interactions in and the
tolerability of combined ARV-based therapy and chemother-
apy, the AIDS Malignancy Consortium, a National Cancer
Institute-sponsored cooperative group, launched a series of
clinical studies in HIV-infected patients with refractory cancers.
These trials have focused on new targeted chemotherapeutic
agents [4]. The investigators stratiﬁed HIV-infected patients
into three groups based on their ARV regimens: (i)
non-NNRTI-based therapy, (ii) non-ritonavir PI-based therapy
and (iii) ritonavir-based therapy; studies are in progress [17]. In
the present study, we found that PI regimens had a poor safety
proﬁle and a signiﬁcantly lower efﬁcacy in comparison with
those of NNRTIs and INSTIs. PI-based treatment appears to
greatly potentiate the myelotoxicity of chemotherapy [18].
Our results support the inclusion of raltegravir-based
regimens in future studies analysing the safety of concomitant
use of chemotherapeutic agents and ARVs. Elvitegravir, one of
the other US Food and Drug Administration-approved INSTI,
is principally metabolized via the CYP450 pathway. Therefore,
interactions of it with several commonly used anticancer drugs
are expected. Dolutegrevir seems to have a safe drug
interaction proﬁle, making it a potential agent in the treatment
of cancer patients with HIV infection [19].
Few studies have addressed the combined use of chemo-
therapeutic agents and ARVs. Most of the studies have focused
on assessment of tumour response and progression with the
use of different chemotherapeutic agents, excluding details
such as type of ARV used and virological outcome [15,20–22].
An unanswered therapeutic question is whether the addition
of cytotoxic chemotherapy to ARV-based treatment causes
signiﬁcant toxic effects or compromises HIV-directed care.
Our results regarding the concomitant use of several classes
of ARVs are reassuring. However, the clinical importance of
complex drug interactions in HIV-infected cancer patients
receiving ARVs and chemotherapy should not be considered
trivial, and patients receiving concomitant chemotherapy and
ARV regimens should be closely monitored. In a study of two
patients with HIV-associated KS who received paclitaxel along
with PI regimens, life-threatening toxic effects developed in
both of them [23]. In the present study, a multidisciplinary
team reviewed the ARV regimens to prevent the occurrence
of clinically relevant drug interactions.
TABLE 4. Side-effects in HIV-infected patients with cancer receiving ARVs
Variable NRTI + INSTI NRTI + PI NRTI + NNRTI Combination p
Side-effectsa (%) 1/30 (3) 17/49 (35) 7/49 (14) 1/17 (6) 0.001b
ARV only (%) 0/1 (0) 8/17 (47) 2/7 (29) 1/1 (100) 0.037c
ARV + chemotherapy (%) 1/1 (100) 9/17 (53) 4/7 (57) 0/1 (0) 0.09
ARV + chemotherapy + other drugs (%) 0/1 (0) 0/17 (0) 1/7 (14) 0/1 (0) >0.99
ARV + progressive cancer (%) 0/1 (0) 5/17 (29) 3/7 (43) 0/1 (0) 1.0
Developed co-infections while on ARV (%) 0/1 (0) 5/17 (29) 3/7 (43) 1/1 (100) 1.0
Length of ARV therapy, months, median (range) 8 (8–8) 65 (28–204) 34 (10–108) 208 (208–208) 0.17
Type of side-effects
CNS (%) 0/1 (0) 0/17 (0) 3/7 (43) 0/1 (0)
Bizarre dreams (%) – – 2/7 (29) –
Dizziness (%) – – 1/7 (14) –
GI (%) 1/1 (100) 4/17 (24) 0/7 (0) 0/1 (0)
Diarrhoea (%) 0/1 (0) 3/17 (18)d – –
Nausea (%) 0/1 (0) 1/17 (6)d – –
GI discomfort (%) 1/1 (100) 0/17 (0) – –
Hepatobiliary (%) 0/1 (0) 2/17 (12) 1/7 (14) 0/1 (0)
Elevated transaminases (%) – 1/17 (6)d 1/7 (14)d –
Hyperbilirubinaemia (%) – 1/17 (6)e 0/7 (0) –
Skin rash (%) 1/1 (100)d 0/17 (0) 1/7 (14)d 0/1 (0)
Renal (%) 0/1 (0) 2/17 (12) 0/7 (0) 0/1 (0)
Acute renal failure (%) – 1/17 (6)e – –
Nephrolithiasis (%) – 1/17 (6)d – –
Lipodystrophy (%) 0/1 (0) 1/17 (6) 1/7 (14) 1/1 (100)
Fat accumulation (%) – 1/17 (6)d – 1/1 (100)d
Lipoatrophy (%) – – 1/7 (14)e –
Hyperlipidaemia (%) 0/1 (0) 3/17 (18) 1/7 (14 0/1 (0)
Cholesterol (%) – 3/17 (18)f – –
Triglycerides (%) – – 1/7 (14)d –
Neuropathy (%) 0/1 (0) 4/17 (24)d 0/7 (0) 0/1 (0)
Osteopenia (%) 0/1 (0) 1/17 (6)d 0/7 (0) 0/1 (0)
CNS, central nervous system; GI, gastrointestinal.
aOne patient may develop more than one side-effect; all side-effects reported occurred within 6 months of initial evaluation.
bNRTI backbone + INSTI vs. NRTI backbone + PI, p 0.001; NRTI backbone + PI vs. NRTI backbone + NNRTI, p 0.02.
cNRTI backbone + INSTI vs. NRTI backbone + PI, p 0.021.
dGrade 1–2 side-effects.
eGrade 3–4 side-effects.
fTwo of the three patients who received NRTI + PI and developed hyperlipidaemia had grade 2 hypercholesterolaemia and one patient had grade 3 hypercholesterolaemia.
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Our study results should be interpreted with caution given
the study’s retrospective nature, small sample size, lack of
information on time of cancer diagnosis, detailed cancer
chemotherapy and changes in supportive care that modiﬁed
cancer outcome (potentially impacting efﬁcacy of INSTIs that
were most recently introduced), and lack of pharmacokinetic
assessment. However, results of pharmacokinetic studies of
chemotherapy and ARVs do not always correlate with clinical
outcome. For example, in a previous study of 34 patients with
advanced HIV-associated KS who received paclitaxel and
ARVs, paclitaxel exposure was higher in patients taking PIs
than in those not taking them, but the increased drug exposure
did not correlate with efﬁcacy or toxicity of paclitaxel [24].
Differences in mortality are likely to reﬂect the outcome of the
different types of cancer, as the most common cause of death
in all treatment groups was progression of cancer.
In conclusion, administration of an INSTI or NNRTI
regimen but not a PI regimen resulted in increased safety
and suppressed viral replication without causing signiﬁcant
adverse events in HIV-infected patients who had cancer or had
undergone HSCT. When interactions of chemotherapeutic
and antifungal agents are anticipated, speciﬁc INSTIs appear to
be the ARVs of choice. Larger prospective studies are required
to further deﬁne the toxicity proﬁles of HIV-infected cancer
patients receiving chemotherapy. Such studies should help aid
the development of speciﬁc guidelines for treatment in this
patient population.
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